摘要
甲状腺癌是最常见的内分泌系统恶性肿瘤,且发病率增长迅速,分化型甲状腺癌(differentiated thyroid carcinoma,DTC)约占甲状腺癌总数的90%。经过规范化的治疗预后良好,但是约5%~10%的DTC会发生术后复发及远处转移,甚至转化为未分化癌,传统的治疗方法对此部分晚期/转移性甲状腺癌疗效有限。近年研究显示免疫治疗能够使甲状腺癌患者获益,有望成为DTC患者新的治疗手段,改善患者预后,而微卫星不稳定(microsatellite instability,MSI)是预测免疫治疗疗效的重要指标之一。因此,检测甲状腺癌MSI的发生率对于筛选可能从免疫检查点抑制剂中获益的患者具有重要的临床意义。本文对MSI及免疫治疗在DTC中的研究进展进行综述,以期为DTC的免疫治疗提供理论依据。
Thyroid cancer is the most common endocrine malignancy,and its incidence is increasing rapidly.Differentiated thyroid carcinoma(DTC)accounts for about 90%of all thyroid cancers,and a favorable prognosis can be obtained after treatment.However,5%-10%of DTC may result in post-operative disease recurrence or even progression to anaplastic thyroid cancer.The curative effects of traditional treatment on these terminal/metastatic thyroid cancers are limited.However,research in recent years has shown that patients with thyroid cancer can benefit from immunotherapy.It is expected to become a new treatment modality to improve the prognosis of these patients.Microsatellite instability(MSI)is an important biomarkers for predicting the therapeutic effect of immunotherapy.Therefore,MSI is important in selecting patients who can benefit from immune checkpoint inhibitors.In this article,we review the current progress in research on MSI and immunotherapy in DTC,in order to provide a theoretical basis for the immunotherapy of DTC.
作者
邱燕如
戴毅君
戴炀斌(综述)
许天文(审校)
Yanru Qiu;Yijun Dai;Yangbin Dai;Tianwen Xu(Department of Medical Oncology,Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第23期1236-1241,共6页
Chinese Journal of Clinical Oncology
关键词
分化型甲状腺癌
微卫星不稳定
免疫治疗
differentiated thyroid carcinoma(DTC)
microsatellite instability(MSI)
immunotherapy
